抑制SNCG阳性表达乳腺癌细胞株MDA-MB231的实验研究 Inhibition of γ-synuclein (SNCG) expression in breast cancer MDA-MB231 cell line.pdfVIP

Chinese-German Journal of Clinical Oncology March 2012, Vol. 11, No. 3, P156–P159 DOI 10.1007/s10330-011-0930-4 Inhibition of γ-synuclein (SNCG) expression in breast cancer MDA-MB231 cell line* Tao Ren, Bangxian Tan, Xiaojie Ma, Yan Gui, Daiyuan Ma, Yeqin Zhou Department of Radiation Oncology, Key Disciplines of Oncology in Sichuan Province, The Affiliated Hospital, North Sichuan Medical College, Nanchong 637000, China Received: 17 November 2011 / Revised: 2 January 2012 / Accepted: 5 February 2012 © Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2012 Abstract Objective: The aim of the study was to evaluate the inhibition of different chemotherapy drugs on γ-synuclein (SNCG) positive expression of breast cancer cell line MDA-MB231, and the effects on cell cycle and apoptosis, and to explore the related mechanism as well. Methods: We treated the breast cancer cell line MDA-MB231 for the inhibition of SNCG with chemotherapy drugs such as irinotecan, nedaplatin and 5-fluorouracil using RT-PCR and immunohistochemistry, and adopted flow cytometry to detect cell cycle distribution and apoptosis. Results: At the transcription and translation levels, the SNCG expression level in nedaplatin group and 5-fluorouracil group was lower than that of other groups and there was statistically significance (P 0.01) compared with the control group, while there was not statistically significant between irinotecan group and the control group. After drugs action, cell cycle and distribution in each experiment group changed obviously, where the cells in G G phase increased, especially the cells in the nedaplatin group and 5-fluorouracil group changed most significantly,